- Activity of fulvestrant in HER2-overexpressing advanced breast cancer2010 | First Faculty of Medicine
- Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology2013 | First Faculty of Medicine
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial2014 | First Faculty of Medicine